Details for Patent: 11,045,461
✉ Email this page to a colleague
Which drugs does patent 11,045,461 protect, and when does it expire?
Patent 11,045,461 protects XOLREMDI and is included in one NDA.
This patent has twelve patent family members in twelve countries.
Summary for Patent: 11,045,461
| Title: | Compositions of CXCR4 inhibitors and methods of preparation and use |
| Abstract: | The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4. |
| Inventor(s): | Brands Karel Marie Joseph |
| Assignee: | X4 PHARMACEUTICALS, INC. |
| Application Number: | US16704302 |
|
Patent Claim Types: see list of patent claims |
Drugs Protected by US Patent 11,045,461
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| X4 Pharms | XOLREMDI | mavorixafor | CAPSULE;ORAL | 218709-001 | Apr 26, 2024 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 11,045,461
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2019328530 | ⤷ Sign Up | |||
| Brazil | 112021003467 | ⤷ Sign Up | |||
| Canada | 3110735 | ⤷ Sign Up | |||
| China | 112839649 | ⤷ Sign Up | |||
| Eurasian Patent Organization | 202190377 | ⤷ Sign Up | |||
| European Patent Office | 3843720 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
